Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 24

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 24
---
S firm. Abstentions and broker non-votes, if any, will not affect the outcome of Proposal Two, other than counting towards the quorum of the meeting. The full text of the resolution to be proposed is as follows: “RESOLVED, as an ordinary resolution, that the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2025 be confirmed, ratified and approved in all respects.” OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 16 TABLE OF CONTENTS PROPOSAL THREE:
ADVISORY VOTE ON EXECUTIVE COMPENSATION We are required by Section 14A of the Exchange Act to give shareholders the right to vote to approve, on an advisory basis, the compensation of our named executive officers. This is commonly referred to as a “Say On Pay” proposal. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. As described further in the “Executive Compensation” section of this proxy statement, beginning on page 31, including the “Narrative Disclosure to Summary Compensation Table,” the primary goals of our compensation programs are to fairly compensate employees, attract and retain highly qualified employees, motivate the performance of our employees towards key corporate goals, reward the achievement of such goals, and align our employees’ long-term interests with those of our shareholders. To this end, the compensation provided to our named executive officers in 2024 included the following features: • We link potential significant compensatory rewards to achievement of corporate operating goals designed to increase shareholder value and align our executives’ interest with those of shareholders through equity incentive compensation which vests over time and gives our executives a direct proprietary interest in our operations and future success. In addition, approximately 50% of each of our named executive officers’ 2024 equity compensation was provided in performance-based restricted share units that vest upon the achievement of three stock price appreciation targets of increasing difficulty. • No changes have been made to Mr. Winningham’s base salary and target bonus since 2021. In addition, Mr. Winningham agreed to use approximately 20% of his 2024 after-tax salary to purchase our ordinary shares. These purchases took place periodically at a purchase price per